Zonegran
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Epilepsy
Conditions
Epilepsy
Trial Timeline
May 1, 2005 → Feb 1, 2008
NCT ID
NCT00165828About Zonegran
Zonegran is a approved stage product being developed by Eisai for Epilepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT00165828. Target conditions include Epilepsy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00215592 | Approved | Completed |
| NCT00165828 | Approved | Terminated |
Competing Products
20 competing products in Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 52 |
| Lacosamide | UCB | Phase 3 | 74 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| Perampanel + Placebo | Eisai | Approved | 85 |
| perampanel | Eisai | Approved | 85 |
| E2007 + Placebo | Eisai | Phase 2 | 52 |
| Placebo + Rufinamide | Eisai | Phase 3 | 77 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 52 |
| Perampanel Oral Tablet | Eisai | Approved | 85 |
| perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Approved | 85 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 33 |
| Perampanel | Eisai | Phase 2 | 52 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 85 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 52 |
| Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/day | Eisai | Approved | 85 |